JP2019512498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512498A5 JP2019512498A5 JP2018548393A JP2018548393A JP2019512498A5 JP 2019512498 A5 JP2019512498 A5 JP 2019512498A5 JP 2018548393 A JP2018548393 A JP 2018548393A JP 2018548393 A JP2018548393 A JP 2018548393A JP 2019512498 A5 JP2019512498 A5 JP 2019512498A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense oligonucleotide
- pharmaceutical composition
- composition according
- conjugate
- oligonucleotide conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16160149 | 2016-03-14 | ||
| EP16160149.7 | 2016-03-14 | ||
| PCT/EP2017/055925 WO2017157899A1 (en) | 2016-03-14 | 2017-03-14 | Oligonucleotides for reduction of pd-l1 expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020106728A Division JP7002603B2 (ja) | 2016-03-14 | 2020-06-22 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512498A JP2019512498A (ja) | 2019-05-16 |
| JP2019512498A5 true JP2019512498A5 (https=) | 2020-04-16 |
| JP6748219B2 JP6748219B2 (ja) | 2020-08-26 |
Family
ID=58314191
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548393A Active JP6748219B2 (ja) | 2016-03-14 | 2017-03-14 | Ｐｄ−ｌ１発現低減用のオリゴヌクレオチド |
| JP2020106728A Active JP7002603B2 (ja) | 2016-03-14 | 2020-06-22 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
| JP2021212541A Active JP7447073B2 (ja) | 2016-03-14 | 2021-12-27 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
| JP2024000251A Active JP7791222B2 (ja) | 2016-03-14 | 2024-01-04 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020106728A Active JP7002603B2 (ja) | 2016-03-14 | 2020-06-22 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
| JP2021212541A Active JP7447073B2 (ja) | 2016-03-14 | 2021-12-27 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
| JP2024000251A Active JP7791222B2 (ja) | 2016-03-14 | 2024-01-04 | Ｐｄ－ｌ１発現低減用のオリゴヌクレオチド |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US20170283496A1 (https=) |
| EP (2) | EP3786297A1 (https=) |
| JP (4) | JP6748219B2 (https=) |
| KR (5) | KR20250065735A (https=) |
| CN (5) | CN114736901B (https=) |
| AR (2) | AR108038A1 (https=) |
| AU (4) | AU2017235278C1 (https=) |
| CA (2) | CA3013683C (https=) |
| CL (4) | CL2018002570A1 (https=) |
| CO (1) | CO2018007761A2 (https=) |
| CR (2) | CR20180432A (https=) |
| DK (1) | DK3430141T3 (https=) |
| ES (1) | ES2857702T3 (https=) |
| HR (1) | HRP20210315T1 (https=) |
| HU (1) | HUE053172T2 (https=) |
| IL (5) | IL296483B2 (https=) |
| LT (1) | LT3430141T (https=) |
| MX (2) | MX2018010830A (https=) |
| MY (1) | MY194912A (https=) |
| PE (3) | PE20230157A1 (https=) |
| PH (1) | PH12018501964A1 (https=) |
| PL (1) | PL3430141T3 (https=) |
| PT (1) | PT3430141T (https=) |
| RS (1) | RS61528B1 (https=) |
| RU (1) | RU2747822C2 (https=) |
| SG (1) | SG11201807854SA (https=) |
| SI (1) | SI3430141T1 (https=) |
| TW (5) | TWI794662B (https=) |
| UA (1) | UA127432C2 (https=) |
| WO (1) | WO2017157899A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2572826C2 (ru) | 2008-12-02 | 2016-01-20 | Чиралджен, Лтд. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| CA2767253A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc. | Novel nucleic acid prodrugs and methods of use thereof |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| AU2012284265B2 (en) | 2011-07-19 | 2017-08-17 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| JP6453212B2 (ja) | 2012-07-13 | 2019-01-16 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | キラル制御 |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| ES2917473T3 (es) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| RU2018106515A (ru) | 2015-07-21 | 2019-08-21 | Зе Чилдрен'С Медикал Сентер Корпорейшн | Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения |
| KR20250065735A (ko) | 2016-03-14 | 2025-05-13 | 에프. 호프만-라 로슈 아게 | Pd-l1 발현의 감소를 위한 올리고뉴클레오티드 |
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| WO2018024849A1 (en) * | 2016-08-03 | 2018-02-08 | Aalborg Universitet | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS |
| US10941402B2 (en) | 2016-09-01 | 2021-03-09 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded RNA-editing oligonucleotides |
| CN110191952A (zh) | 2016-10-07 | 2019-08-30 | 瑟卡尔纳制药有限公司 | 治疗癌症的新方法 |
| WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
| UA126931C2 (uk) | 2017-10-16 | 2023-02-22 | Ф. Хоффманн-Ля Рош Аг | МОЛЕКУЛИ НУКЛЕЇНОВИХ КИСЛОТ ДЛЯ ЗМЕНШЕННЯ РІВНЯ мРНК PAPD5 І PAPD7 ДЛЯ ЛІКУВАННЯ ІНФЕКЦІЙНОГО ГЕПАТИТУ B |
| SI3684377T1 (sl) | 2017-10-20 | 2023-05-31 | Dicerna Pharmaceuticals, Inc. | Postopki zdravljenja okužbe s hepatitisom B |
| EA202091693A1 (ru) | 2018-01-12 | 2021-04-14 | Бристол-Маерс Сквибб Компани | Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения |
| BR112020013994A2 (pt) | 2018-01-12 | 2020-12-08 | Bristol-Myers Squibb Company | Oligonucleotídeos antissenso que direcionam alfa-sinucleína e seus usos |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| MX2020013930A (es) | 2018-06-22 | 2021-03-09 | Hoffmann La Roche | Oligonucleotidos para modular la expresion del canal de sodio dependiente de voltaje alfa subunidad 9 (scn9a). |
| WO2020007772A1 (en) * | 2018-07-02 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting gbp-1 |
| WO2020011653A1 (en) * | 2018-07-09 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting kynu |
| EP4512407A3 (en) | 2018-07-13 | 2025-09-24 | F. Hoffmann-La Roche AG | Oligonucleotides for modulating rtel1 expression |
| US20210380978A1 (en) * | 2018-10-15 | 2021-12-09 | The Brigham And Women`S Hospital, Inc. | The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy |
| WO2020178258A1 (en) * | 2019-03-05 | 2020-09-10 | F. Hoffmann-La Roche Ag | Intracellular targeting of molecules |
| US20220177894A1 (en) | 2019-04-02 | 2022-06-09 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for immunotherapy |
| JP2022532998A (ja) * | 2019-04-26 | 2022-07-21 | ストーク セラピューティクス，インク． | 選択的イントロンのスプライシングを調節するための方法及び組成物 |
| AU2020269886A1 (en) | 2019-05-03 | 2021-12-02 | Secarna Pharmaceuticals Gmbh & Co. Kg | PD-L1 antisense oligonucleotides for use in tumor treatment |
| CN114901821A (zh) * | 2019-12-19 | 2022-08-12 | 豪夫迈·罗氏有限公司 | Sept9抑制剂用于治疗乙型肝炎病毒感染的用途 |
| JP2023506550A (ja) * | 2019-12-19 | 2023-02-16 | エフ． ホフマン－ラ ロシュ エージー． | Ｂ型肝炎ウイルス感染症を処置するためのｓｂｄｓ阻害剤の使用 |
| EP4077672A1 (en) * | 2019-12-20 | 2022-10-26 | F. Hoffmann-La Roche AG | Enhanced oligonucleotides for inhibiting scn9a expression |
| CN114828852A (zh) * | 2019-12-24 | 2022-07-29 | 豪夫迈·罗氏有限公司 | 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合 |
| WO2021173812A1 (en) * | 2020-02-28 | 2021-09-02 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
| CA3190794A1 (en) | 2020-08-05 | 2022-02-10 | Soren Ottosen | Oligonucleotide treatment of hepatitis b patients |
| CN114507663A (zh) * | 2020-11-16 | 2022-05-17 | 浙江柏拉阿图医药科技有限公司 | 寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用 |
| TW202246500A (zh) * | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| CN115216474B (zh) * | 2021-04-15 | 2025-09-30 | 武汉大学 | 促进pd-l1外显子3跳跃的反义寡核苷酸及其应用 |
| JP2024528270A (ja) * | 2021-08-04 | 2024-07-26 | ヘパジーン セラピューティクス（エイチケー）リミティド | 治療活性剤の送達のためのリガンド共役体 |
| CN113789324B (zh) * | 2021-08-17 | 2023-08-25 | 广东省大湾区华南理工大学聚集诱导发光高等研究院 | 一种aie探针及其制备方法与在荧光定量pcr方法中的应用 |
| CA3234478A1 (en) | 2021-11-11 | 2023-05-19 | Souphalone LUANGSAY | Pharmaceutical combinations for treatment of hbv |
| WO2024011109A2 (en) * | 2022-07-06 | 2024-01-11 | Adverum Biotechnologies, Inc. | Compositions and methods for treatment of achromotopsia |
| CN116597936A (zh) * | 2023-01-30 | 2023-08-15 | 溪砾科技(深圳)有限公司 | 一种识别mRNA非翻译区药物作用靶点的方法、装置及计算机可读存储介质 |
| CN121488037A (zh) * | 2023-07-20 | 2026-02-06 | 上海舶望制药有限公司 | 用于抑制pd-l1表达的组合物和方法 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5927900A (ja) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
| US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
| US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
| US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
| US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
| DE3738460A1 (de) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | Modifizierte oligonukleotide |
| US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
| US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
| WO1993007883A1 (en) | 1991-10-24 | 1993-04-29 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
| US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
| RU2123528C1 (ru) * | 1990-11-08 | 1998-12-20 | Чирон Корпорейшн | Способ получения белков hcv, пригодных для использования в вакцине или иммуноанализе, асиалогликопротеин (варианты), композиция для использования в вакцине или в иммуноанализе (варианты), способ очистки асиалогликопротеина и способ понижения содержания или элиминации hcv |
| WO1992008728A1 (en) | 1990-11-08 | 1992-05-29 | Hybridon, Inc. | Incorporation of multiple reporter groups on synthetic oligonucleotides |
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
| PT804456E (pt) | 1994-10-06 | 2003-01-31 | Peter Eigil Nielsen | Conjugados de acidos nucleicos dos peptidos |
| US5684142A (en) | 1995-06-07 | 1997-11-04 | Oncor, Inc. | Modified nucleotides for nucleic acid labeling |
| AU1039397A (en) | 1995-11-22 | 1997-06-27 | Johns Hopkins University, The | Ligands to enhance cellular uptake of biomolecules |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US5770716A (en) | 1997-04-10 | 1998-06-23 | The Perkin-Elmer Corporation | Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same |
| IL132941A0 (en) | 1997-05-21 | 2001-03-19 | Univ Leland Stanford Junior | Composition and method for enhancing transport across biological membranes |
| AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
| US6096875A (en) | 1998-05-29 | 2000-08-01 | The Perlein-Elmer Corporation | Nucleotide compounds including a rigid linker |
| US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
| US6335432B1 (en) | 1998-08-07 | 2002-01-01 | Bio-Red Laboratories, Inc. | Structural analogs of amine bases and nucleosides |
| US6335437B1 (en) | 1998-09-07 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Methods for the preparation of conjugated oligomers |
| CZ296576B6 (cs) | 1999-02-12 | 2006-04-12 | Sankyo Company Limited | Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem |
| EP1178999B1 (en) | 1999-05-04 | 2007-03-14 | Santaris Pharma A/S | L-ribo-lna analogues |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| US20060276422A1 (en) | 2001-05-18 | 2006-12-07 | Nassim Usman | RNA interference mediated inhibition of B7-H1 gene expression using short interfering nucleic acid (siNA) |
| WO2005007855A2 (en) | 2003-07-14 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF B7-H1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| ES2350687T3 (es) * | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| US9045518B2 (en) | 2002-11-18 | 2015-06-02 | Santaris Pharma A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
| HUE042261T2 (hu) | 2003-06-12 | 2019-06-28 | Alnylam Pharmaceuticals Inc | Gén kikapcsolásra alkalmas konzervált HBV és HCV szekvenciák |
| DE60319354T2 (de) | 2003-07-11 | 2009-03-26 | Lbr Medbiotech B.V. | Mannose-6-Phosphat Rezeptor vermittelter Gentransfer zu Muskelzellen |
| ES2671893T3 (es) * | 2004-10-06 | 2018-06-11 | Mayo Foundation For Medical Education And Research | B7-H1 y PD-1 en el tratamiento del carcinoma de células renales |
| ZA200703482B (en) * | 2004-10-06 | 2008-09-25 | Mayo Foundation | B7-H1 and methods of diagnosis, prognosis, and treatment of cancer |
| US20120122801A1 (en) | 2005-01-05 | 2012-05-17 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
| CN101355965A (zh) | 2005-06-08 | 2009-01-28 | 达纳－法伯癌症研究院 | 通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物 |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| JP5342881B2 (ja) | 2006-01-27 | 2013-11-13 | アイシス ファーマシューティカルズ， インコーポレーテッド | ６−修飾された二環式核酸類似体 |
| EP2023940B1 (en) | 2006-05-05 | 2011-06-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of sglt2 |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
| CN103536915A (zh) | 2006-12-27 | 2014-01-29 | 埃默里大学 | 用于治疗传染病和肿瘤的组合物和方法 |
| WO2008113832A2 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
| EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| CA2692579C (en) | 2007-07-05 | 2016-05-03 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
| WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
| DK2285819T3 (da) | 2008-04-04 | 2013-12-02 | Isis Pharmaceuticals Inc | Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider |
| WO2009126933A2 (en) | 2008-04-11 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| CA2744449C (en) | 2008-11-28 | 2019-01-29 | Emory University | Methods for the treatment of infections and tumors |
| AU2009333580B2 (en) * | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| US9181525B2 (en) * | 2009-03-06 | 2015-11-10 | Mie University | Method for enhancing a function of a T cell |
| CN102459596B (zh) * | 2009-05-06 | 2016-09-07 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
| KR101704988B1 (ko) * | 2009-05-28 | 2017-02-08 | 큐알엔에이, 인크. | 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료 |
| EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| CA2792561C (en) * | 2010-04-06 | 2021-10-26 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of cd274/pd-l1 gene |
| US8765708B2 (en) * | 2010-05-18 | 2014-07-01 | Kevin Petrecca | Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas |
| EP2580228B1 (en) | 2010-06-08 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| WO2012024170A2 (en) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| LT3124610T (lt) | 2010-10-28 | 2019-08-12 | Benitec Biopharma Limited | Hbv gydymas |
| EP2652134B1 (en) | 2010-12-17 | 2017-03-01 | Arrowhead Pharmaceuticals, Inc. | Galactose cluster-pharmacokinetic modulator targeting moiety for sirna |
| ES2605990T3 (es) | 2010-12-29 | 2017-03-17 | F. Hoffmann-La Roche Ag | Conjugados de molécula pequeña para la administración intracelular de ácidos nucleicos |
| PH12019502377A1 (en) | 2011-04-21 | 2022-11-14 | Isis Pharmaceuticals Inc | Modulation of hepatitis b virus (hbv) expression |
| HRP20181564T1 (hr) | 2011-06-30 | 2018-11-30 | Arrowhead Pharmaceuticals, Inc. | Pripravci i postupci za inhibiciju ekspresije gena virusa hepatitisa b |
| AU2012284265B2 (en) | 2011-07-19 | 2017-08-17 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| EP3453761A1 (en) | 2011-08-29 | 2019-03-13 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| CN104136451A (zh) | 2011-09-07 | 2014-11-05 | 玛瑞纳生物技术有限公司 | 具有构象限制的单体的核酸化合物的合成和用途 |
| WO2013049307A2 (en) | 2011-09-30 | 2013-04-04 | University Of Miami | Enhanced immune memory development by aptamer targeted mtor inhibition of t cells |
| HUE059406T2 (hu) * | 2011-10-17 | 2022-11-28 | Io Biotech Aps | PD-L1 alapú immunterápia |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| JP2016528873A (ja) | 2012-05-16 | 2016-09-23 | ラナ セラピューティクス インコーポレイテッド | 遺伝子発現を調節するための組成物及び方法 |
| CA2873766A1 (en) * | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating atp2a2 expression |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| US10077443B2 (en) | 2012-11-15 | 2018-09-18 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
| KR102291355B1 (ko) | 2012-11-30 | 2021-08-19 | 에프. 호프만-라 로슈 아게 | Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법 |
| WO2014118272A1 (en) * | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
| CN104955952A (zh) * | 2013-01-30 | 2015-09-30 | 弗·哈夫曼-拉罗切有限公司 | Lna寡核苷酸碳水化合物缀合物 |
| DK2991656T3 (da) | 2013-05-01 | 2020-03-23 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression |
| ES2770667T3 (es) | 2013-06-27 | 2020-07-02 | Roche Innovation Ct Copenhagen As | Oligómeros antisentido y conjugados que se dirigen a PCSK9 |
| WO2015114146A1 (en) * | 2014-02-03 | 2015-08-06 | Sividon Diagnostics Gmbh | Method for predicting the response to an anti-her2 containing therapy and/or chemotherapy in patients with breast cancer |
| US20170224777A1 (en) | 2014-08-12 | 2017-08-10 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
| WO2016055601A1 (en) | 2014-10-10 | 2016-04-14 | F. Hoffmann-La Roche Ag | Galnac phosphoramidites, nucleic acid conjugates thereof and their use |
| WO2016138278A2 (en) | 2015-02-27 | 2016-09-01 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting checkpoint gene expression and uses thereof |
| GB201507926D0 (en) * | 2015-05-08 | 2015-06-24 | Proqr Therapeutics N V | Improved treatments using oligonucleotides |
| US10577388B2 (en) * | 2015-10-02 | 2020-03-03 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugation process |
| MX378999B (es) | 2015-11-16 | 2025-03-10 | Hoffmann La Roche | Fosforamidita de agrupacion de n-acetilgalactosamina (galnac). |
| WO2017100587A1 (en) | 2015-12-09 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting programmed cell death 1 ligand 1 (pd-l1) and methods of use thereof |
| KR20250065735A (ko) | 2016-03-14 | 2025-05-13 | 에프. 호프만-라 로슈 아게 | Pd-l1 발현의 감소를 위한 올리고뉴클레오티드 |
| WO2018215049A1 (en) | 2017-05-23 | 2018-11-29 | F. Hoffmann-La Roche Ag | Process for galnac oligonucleotide conjugates |
-
2017
- 2017-03-14 KR KR1020257014623A patent/KR20250065735A/ko active Pending
- 2017-03-14 CA CA3013683A patent/CA3013683C/en active Active
- 2017-03-14 KR KR1020187026546A patent/KR102306797B1/ko active Active
- 2017-03-14 LT LTEP17710874.3T patent/LT3430141T/lt unknown
- 2017-03-14 UA UAA201810179A patent/UA127432C2/uk unknown
- 2017-03-14 IL IL296483A patent/IL296483B2/en unknown
- 2017-03-14 IL IL317818A patent/IL317818A/en unknown
- 2017-03-14 CN CN202210443059.2A patent/CN114736901B/zh active Active
- 2017-03-14 CN CN202111366505.6A patent/CN114085836B/zh active Active
- 2017-03-14 TW TW109135754A patent/TWI794662B/zh active
- 2017-03-14 CA CA3120687A patent/CA3120687A1/en active Pending
- 2017-03-14 MX MX2018010830A patent/MX2018010830A/es unknown
- 2017-03-14 CN CN202210442730.1A patent/CN114736900B/zh active Active
- 2017-03-14 IL IL303077A patent/IL303077B2/en unknown
- 2017-03-14 TW TW111134997A patent/TWI840950B/zh active
- 2017-03-14 HR HRP20210315TT patent/HRP20210315T1/hr unknown
- 2017-03-14 TW TW109135755A patent/TWI790485B/zh active
- 2017-03-14 CN CN202210440723.8A patent/CN114717235A/zh active Pending
- 2017-03-14 PE PE2022000852A patent/PE20230157A1/es unknown
- 2017-03-14 PL PL17710874T patent/PL3430141T3/pl unknown
- 2017-03-14 CR CR20180432A patent/CR20180432A/es unknown
- 2017-03-14 AR ARP170100626A patent/AR108038A1/es unknown
- 2017-03-14 ES ES17710874T patent/ES2857702T3/es active Active
- 2017-03-14 PT PT177108743T patent/PT3430141T/pt unknown
- 2017-03-14 KR KR1020237031671A patent/KR102805002B1/ko active Active
- 2017-03-14 EP EP20201780.2A patent/EP3786297A1/en active Pending
- 2017-03-14 AU AU2017235278A patent/AU2017235278C1/en active Active
- 2017-03-14 EP EP17710874.3A patent/EP3430141B1/en active Active
- 2017-03-14 RS RS20210240A patent/RS61528B1/sr unknown
- 2017-03-14 SG SG11201807854SA patent/SG11201807854SA/en unknown
- 2017-03-14 TW TW113111556A patent/TW202428874A/zh unknown
- 2017-03-14 US US15/458,800 patent/US20170283496A1/en not_active Abandoned
- 2017-03-14 SI SI201730645T patent/SI3430141T1/sl unknown
- 2017-03-14 RU RU2018134379A patent/RU2747822C2/ru active
- 2017-03-14 CN CN201780017220.7A patent/CN108779465B/zh active Active
- 2017-03-14 WO PCT/EP2017/055925 patent/WO2017157899A1/en not_active Ceased
- 2017-03-14 MY MYPI2018703228A patent/MY194912A/en unknown
- 2017-03-14 CR CR20200119A patent/CR20200119A/es unknown
- 2017-03-14 KR KR1020217030513A patent/KR102417646B1/ko active Active
- 2017-03-14 KR KR1020227022628A patent/KR102580776B1/ko active Active
- 2017-03-14 HU HUE17710874A patent/HUE053172T2/hu unknown
- 2017-03-14 PE PE2020000807A patent/PE20201499A1/es unknown
- 2017-03-14 JP JP2018548393A patent/JP6748219B2/ja active Active
- 2017-03-14 DK DK17710874.3T patent/DK3430141T3/da active
- 2017-03-14 TW TW106108305A patent/TWI721128B/zh active
- 2017-03-14 PE PE2018001567A patent/PE20181892A1/es unknown
-
2018
- 2018-07-24 IL IL260759A patent/IL260759B/en unknown
- 2018-07-26 CO CONC2018/0007761A patent/CO2018007761A2/es unknown
- 2018-09-07 CL CL2018002570A patent/CL2018002570A1/es unknown
- 2018-09-07 MX MX2022012221A patent/MX2022012221A/es unknown
- 2018-09-12 PH PH12018501964A patent/PH12018501964A1/en unknown
-
2019
- 2019-10-25 US US16/664,749 patent/US10745480B2/en active Active
-
2020
- 2020-03-31 CL CL2020000865A patent/CL2020000865A1/es unknown
- 2020-04-02 US US16/839,025 patent/US10829555B2/en active Active
- 2020-04-17 AR ARP200101090A patent/AR118719A2/es unknown
- 2020-04-28 CL CL2020001127A patent/CL2020001127A1/es unknown
- 2020-04-28 CL CL2020001126A patent/CL2020001126A1/es unknown
- 2020-06-22 JP JP2020106728A patent/JP7002603B2/ja active Active
- 2020-08-21 US US17/000,203 patent/US11466081B2/en active Active
-
2021
- 2021-09-20 AU AU2021236439A patent/AU2021236439B2/en active Active
- 2021-12-27 JP JP2021212541A patent/JP7447073B2/ja active Active
-
2022
- 2022-02-01 IL IL290294A patent/IL290294B2/en unknown
- 2022-04-13 AU AU2022202479A patent/AU2022202479B2/en active Active
- 2022-10-07 US US18/045,109 patent/US12552862B2/en active Active
-
2024
- 2024-01-04 JP JP2024000251A patent/JP7791222B2/ja active Active
- 2024-05-29 AU AU2024203581A patent/AU2024203581A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512498A5 (https=) | ||
| JP2021072862A5 (https=) | ||
| IL317818A (en) | Oligonucleotides to reduce PD-L1 expression | |
| JP2020022483A5 (https=) | ||
| JP2017505623A5 (https=) | ||
| KR101764427B1 (ko) | 미셀성 어셈블리 | |
| JP6649248B2 (ja) | 細胞取り込みの向上のための化合物および方法 | |
| US9943604B2 (en) | Targeted therapeutic nucleosides and their use | |
| KR102627418B1 (ko) | 변형된 올리고뉴클레오티드 및 사용 방법 | |
| US20130011362A1 (en) | Targeting monomers and polymers having targeting blocks | |
| IL300119A (en) | Oligonucleotides to induce paternal UBE3A expression | |
| HRP20250408T1 (hr) | Kojugati i njihova priprema i uporaba | |
| JP2018523668A5 (https=) | ||
| HRP20250974T1 (hr) | Oligomeri i oligomerni konjugati | |
| RS62523B1 (sr) | Kompozicije i postupci za inhibiciju genske ekspresije lpa | |
| JP2010532168A5 (https=) | ||
| RU2017139121A (ru) | Композиции для модулирования экспрессии c9orf72 | |
| JP2017513469A5 (https=) | ||
| MX2010012236A (es) | Portador polimerico. | |
| TW201639962A (zh) | Ｒｎａ干擾劑 | |
| JP2009524696A5 (https=) | ||
| WO2009140423A2 (en) | Targeted polymer bioconjugates | |
| EP4146280A1 (en) | Linker compounds | |
| WO2011060281A1 (en) | Hydrophobic block conjugated therapeutic agents | |
| RU2019143004A (ru) | Антисмысловые олигонуклеотиды для модулирования экспрессии htra1 |